1. Home
  2. WTFC vs IMVT Comparison

WTFC vs IMVT Comparison

Compare WTFC & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wintrust Financial Corporation

WTFC

Wintrust Financial Corporation

HOLD

Current Price

$145.81

Market Cap

10.3B

Sector

Finance

ML Signal

HOLD

Logo Immunovant Inc.

IMVT

Immunovant Inc.

HOLD

Current Price

$37.21

Market Cap

8.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WTFC
IMVT
Founded
1991
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.3B
8.5B
IPO Year
1996
2019

Fundamental Metrics

Financial Performance
Metric
WTFC
IMVT
Price
$145.81
$37.21
Analyst Decision
Strong Buy
Buy
Analyst Count
14
8
Target Price
$168.07
$33.00
AVG Volume (30 Days)
366.3K
1.1M
Earning Date
04-20-2026
05-28-2026
Dividend Yield
1.49%
N/A
EPS Growth
10.57
N/A
EPS
6.52
N/A
Revenue
N/A
N/A
Revenue This Year
$13.96
N/A
Revenue Next Year
$6.54
N/A
P/E Ratio
$22.56
N/A
Revenue Growth
N/A
N/A
52 Week Low
$119.67
$15.00
52 Week High
$167.22
$45.42

Technical Indicators

Market Signals
Indicator
WTFC
IMVT
Relative Strength Index (RSI) 33.17 40.11
Support Level $143.58 $37.16
Resistance Level $148.87 $41.22
Average True Range (ATR) 2.64 1.24
MACD -0.25 -0.22
Stochastic Oscillator 17.48 29.00

Price Performance

Historical Comparison
WTFC
IMVT

About WTFC Wintrust Financial Corporation

Wintrust Financial Corp is a financial holding company that provides community-oriented, personal, and commercial banking services to customers generally located in the Chicago metropolitan area, southern Wisconsin, northwest Indiana, and western Michigan. The company provides specialty finance services, including financing for the payment of property and casualty insurance premiums and life insurance premiums, and wealth management services to customers in its market area. Its operations consist of three primary segments: community banking, specialty finance, and wealth management. The company generates the majority of its revenue from the community banking segment.

About IMVT Immunovant Inc.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.

Share on Social Networks: